EGFR and non-small cell lung carcinoma: EGFR TKI has been approved by the FDA as the standard of care for the first-line treatment of patients with metastatic NSCLC harboring EGFR activating mutations with favorable clinical response (80%) and better survival outcome compared with those patients with wild-type EGFR-expressing NSCLC (EGFRWT NSCLC) [3].